GANX Gain Therapeutics Inc
Price (delayed)
$1.47
Market cap
$37.54M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.3
Enterprise value
$21.41M
Gain Therapeutics, Inc. is redefining drug discovery with its See-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new
Highlights
GANX's equity is up by 36% since the previous quarter and by 6% year-on-year
The EPS has grown by 29% YoY and by 13% from the previous quarter
GANX's quick ratio is down by 10% YoY but it is up by 2.8% QoQ
The net income is down by 2.2% since the previous quarter but it is up by 2.1% year-on-year
GANX's revenue has plunged by 100% YoY
Gain Therapeutics's gross profit has shrunk by 100% YoY
Key stats
What are the main financial stats of GANX
Market
Valuations
Earnings
Shares outstanding
25.54M
Market cap
$37.54M
Enterprise value
$21.41M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.25
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$21.54M
EBITDA
-$21.46M
Free cash flow
-$18.99M
Per share
Balance sheet
Liquidity
EPS
-$1.3
Free cash flow per share
-$0.99
Book value per share
$0.65
Revenue per share
$0
TBVPS
$0.99
Total assets
$19.2M
Total liabilities
$7.41M
Debt
$807,570
Equity
$11.78M
Working capital
$12.02M
Debt to equity
0.07
Current ratio
2.84
Quick ratio
2.6
Net debt/EBITDA
0.75
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-130%
Return on equity
-214.2%
Return on invested capital
-2,362%
Return on capital employed
-170%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GANX stock price
How has the Gain Therapeutics stock price performed over time
Intraday
-2%
1 week
-1.34%
1 month
11.36%
1 year
-58.47%
YTD
-55.05%
QTD
14.84%
Financial performance
How have Gain Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$21.85M
Net income
-$21.6M
Gross margin
N/A
Net margin
N/A
GANX's revenue has plunged by 100% YoY
Gain Therapeutics's gross profit has shrunk by 100% YoY
The net income is down by 2.2% since the previous quarter but it is up by 2.1% year-on-year
GANX's operating income is down by 2.1% QoQ
Growth
What is Gain Therapeutics's growth rate over time
Valuation
What is Gain Therapeutics stock price valuation
P/E
N/A
P/B
2.25
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 29% YoY and by 13% from the previous quarter
The stock's price to book (P/B) is 49% less than its last 4 quarters average of 4.5
GANX's equity is up by 36% since the previous quarter and by 6% year-on-year
GANX's revenue has plunged by 100% YoY
Efficiency
How efficient is Gain Therapeutics business performance
Gain Therapeutics's return on equity has shrunk by 65% YoY
GANX's return on assets is down by 36% year-on-year
Dividends
What is GANX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GANX.
Financial health
How did Gain Therapeutics financials performed over time
GANX's total assets is 159% greater than its total liabilities
GANX's total assets is up by 32% since the previous quarter and by 5% year-on-year
Gain Therapeutics's total liabilities has increased by 25% from the previous quarter and by 3.4% YoY
Gain Therapeutics's debt is 93% lower than its equity
GANX's equity is up by 36% since the previous quarter and by 6% year-on-year
GANX's debt to equity is down by 30% since the previous quarter and by 30% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.